Hydrocephalus treatment in patients with craniosynostosis: an analysis from the Hydrocephalus Clinical Research Network prospective registry.


Journal

Neurosurgical focus
ISSN: 1092-0684
Titre abrégé: Neurosurg Focus
Pays: United States
ID NLM: 100896471

Informations de publication

Date de publication:
04 2021
Historique:
received: 13 11 2020
accepted: 06 01 2021
entrez: 1 4 2021
pubmed: 2 4 2021
medline: 22 9 2021
Statut: ppublish

Résumé

Hydrocephalus may be seen in patients with multisuture craniosynostosis and, less commonly, single-suture craniosynostosis. The optimal treatment for hydrocephalus in this population is unknown. In this study, the authors aimed to evaluate the success rate of ventriculoperitoneal shunt (VPS) treatment and endoscopic third ventriculostomy (ETV) both with and without choroid plexus cauterization (CPC) in patients with craniosynostosis. Utilizing the Hydrocephalus Clinical Research Network (HCRN) Core Data Project (Registry), the authors identified all patients who underwent treatment for hydrocephalus associated with craniosynostosis. Descriptive statistics, demographics, and surgical outcomes were evaluated. In total, 42 patients underwent treatment for hydrocephalus associated with craniosynostosis. The median gestational age at birth was 39.0 weeks (IQR 38.0, 40.0); 55% were female and 60% were White. The median age at first craniosynostosis surgery was 0.6 years (IQR 0.3, 1.7), and at the first permanent hydrocephalus surgery it was 1.2 years (IQR 0.5, 2.5). Thirty-three patients (79%) had multiple different sutures fused, and 9 had a single suture: 3 unicoronal (7%), 3 sagittal (7%), 2 lambdoidal (5%), and 1 unknown (2%). Syndromes were identified in 38 patients (90%), with Crouzon syndrome being the most common (n = 16, 42%). Ten patients (28%) received permanent hydrocephalus surgery before the first craniosynostosis surgery. Twenty-eight patients (67%) underwent VPS treatment, with the remaining 14 (33%) undergoing ETV with or without CPC (ETV ± CPC). Within 12 months after initial hydrocephalus intervention, 14 patients (34%) required revision (8 VPS and 6 ETV ± CPC). At the most recent follow-up, 21 patients (50%) required a revision. The revision rate decreased as age increased. The overall infection rate was 5% (VPS 7%, 0% ETV ± CPC). This is the largest prospective study reported on children with craniosynostosis and hydrocephalus. Hydrocephalus in children with craniosynostosis most commonly occurs in syndromic patients and multisuture fusion. It is treated at varying ages; however, most patients undergo surgery for craniosynostosis prior to hydrocephalus treatment. While VPS treatment is performed more frequently, VPS and ETV are both reasonable options, with decreasing revision rates with increasing age, for the treatment of hydrocephalus associated with craniosynostosis.

Identifiants

pubmed: 33794488
doi: 10.3171/2021.1.FOCUS20979
pii: 2021.1.FOCUS20979
doi:
pii:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

E11

Auteurs

Christopher M Bonfield (CM)

1Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, Tennessee.

Chevis N Shannon (CN)

1Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, Tennessee.

Ron W Reeder (RW)

Departments of2Pediatrics and.

Samuel Browd (S)

3Department of Neurosurgery, University of Washington, Seattle, Washington.

James Drake (J)

4Division of Neurosurgery, University of Toronto, Ontario, Canada.

Jason S Hauptman (JS)

3Department of Neurosurgery, University of Washington, Seattle, Washington.

Abhaya V Kulkarni (AV)

4Division of Neurosurgery, University of Toronto, Ontario, Canada.

David D Limbrick (DD)

5Department of Neurosurgery, Washington University School of Medicine in St. Louis, Missouri.

Patrick J McDonald (PJ)

6Division of Neurosurgery, University of British Columbia, Vancouver, British Columbia, Canada.

Robert Naftel (R)

1Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, Tennessee.

Ian F Pollack (IF)

7Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Jay Riva-Cambrin (J)

8Division of Neurosurgery, University of Calgary, Alberta, Canada.

Curtis Rozzelle (C)

9Department of Neurosurgery, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama; and.

Mandeep S Tamber (MS)

6Division of Neurosurgery, University of British Columbia, Vancouver, British Columbia, Canada.

William E Whitehead (WE)

10Department of Neurosurgery, Baylor College of Medicine, Houston, Texas.

John R W Kestle (JRW)

11Neurosurgery, University of Utah, Salt Lake City, Utah.

John C Wellons (JC)

1Department of Neurosurgery, Vanderbilt University Medical Center, Nashville, Tennessee.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH